Interestingly, there is a proclivity of disseminated Aspergillus infection to the CNS in patients treated with a BTK inhibitor, with 40%–60% of IBT-associated aspergillosis presenting cerebrally (20, 43, 67, 68). Here, BTK is linked to aspergillosis.